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Expanding the role of radiographers in reporting suspected lung cancer: a cost-effectiveness 
analysis using a decision tree model 
 
Introduction 
To assess whether an enhanced role for radiographers in reporting lung cancer chest radiographs is 
cost-effective. 
Methods 
Costs and outcomes of chest radiograph reporting by reporting radiographer or by a radiologist were 
compared using a decision tree model. The model followed patients from an initial chest radiographs 
for suspected lung cancer to the provision of cancer care in positive cases. Sensitivity and specificity 
of reporting for radiographers and radiologists were derived from a recent trial. Treatment costs and 
quality adjusted life expectancy were estimated over five years for those diagnosed.  Deterministic 
and probabilistic sensitivity analyses were used to test the robustness of inference to parameter 
uncertainty. 
Results 
For 1,000 simulated patients, radiographer reporting decreased detection costs by £8,500 and 
detected 10.3 more cases at initial presentation. After including treatment costs and outcomes, 
radiographer reporting remained cheaper than radiologist reporting and resulted in 1.4 additional 
QALYs per 1,000 screened patients. Probabilistic analysis indicated a 98% likelihood that 
radiographer reporting is cheaper and more effective than radiologist reporting after inclusion of 
treatment costs and outcomes. 
Conclusion 
Radiographer reporting is a cost-effective alternative to radiologist reporting in lung cancer 
diagnosis. Further work is needed to support the adoption of radiographer’s reporting pathway in 
diagnosis of lung cancer suspected patients. 
Word count - 2483 
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Highlights 
 Reporting of chest radiographs for lung cancer by trained reporting radiographers is cost-
effective 
 Findings are robust to uncertainty in estimates of the specificity and sensitivity of 
radiographer and radiologist reporting 
 Radiographer reporting remains cost-effective for reporting times up to fivefold more than 
reporting times for radiologists  
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 Reporting radiographers can increase diagnostic capacity within the lung cancer pathway   
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Introduction 
Imaging has seen sustained growth in activity, driven by an ageing population, new and emerging 
technologies and a drive to improve patient experience and outcomes.1,2 Diagnostic capacity is 
frequently identified as a barrier to improved patient outcomes,3,4 due to rising demand and chronic 
shortages of consultant radiologists in the United Kingdom,5 for all diagnoses but especially cancer.3 
Maximising the contribution of all members of the diagnostic team is central to improving capacity, 
efficiency and the patient experience. It also aligns with national principles outlined by Health 
Education England in supporting the development of Advanced Clinical Practice delivered by 
experienced registered healthcare practitioners.6  The reporting of imaging examinations by 
appropriately trained radiographers has been advocated for some time.7-9 The joint position of the 
Royal College of Radiologists (RCR) and Society and College of Radiographers (SCOR) is that any 
radiographer undertaking clinical reporting must perform at a level comparable to that of a 
consultant radiologist.10 There is extensive evidence that suggests this is achievable across a 
spectrum of modalities and anatomical regions.7,9,11-15  
The majority of studies addressing clinical reporting by trained radiographers have focused on 
diagnostic accuracy. Excellent sensitivity and specificity has been reported for radiographer 
reporting of skeletal radiographs,7,11,12  chest radiographs (CXR),14,16 magnetic resonance imaging of 
the knee and lumbar spine,13,17 and screening mammography.15 Limited evidence exists on the cost 
effectiveness of radiographer reporting. Radiographer reporting of emergency department musculo-
skeletal examinations was shown to reduce diagnostic errors and cost.18 Work by Woznitza and 
colleagues suggests that integrated radiographer reporting can contribute to the delivery of effective 
and efficient imaging services.19 Despite recognition of the potential for an increased role for 
radiographers within radiology, implementation across England has been patchy.20  
An important area in which radiographers may contribute to streamlined patient pathways and 
increase diagnostic capacity is in reporting CXR for suspected lung cancer. Around seven million CXR 
were performed in the NHS in England in 2015-16 and the numbers are rising.2 Current guidelines 
from the National Institute of Health and Care Excellence (NICE) recommend a CXR for persistent 
symptoms of haemoptysis, dyspnoea, chest pain, cough or weight loss with suspected lung cancer 
cases confirmed by computed tomography (CT) scan.21 Historically, CXRs were only reported by 
consultant radiologists. Now an increasing number of trained reporting radiographers perform this 
role.   
Early diagnosis of lung cancer is essential, and England has worse outcomes compared with many 
other countries.22 Missed cases and delayed diagnosis are likely to narrow treatment options and 
worsen prognosis, impacting on downstream treatment costs and outcomes. There is an extensive 
literature comparing radiographer and radiologist reporting which indicates similar diagnostic 
performance.12 However, few studies have evaluated the cost-effectiveness of radiographer 
reporting compared with radiologist reporting.18,23,24 Hence, the likelihood of lower reporting costs 
for radiographers when compared with radiologists may not translate into a cost-effective use of 
health care resources. In this paper we use a decision model to assess the cost-effectiveness of 
reporting of CXR by trained radiographers compared with radiologists.  
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Methods 
We compared the costs and outcomes of trained radiographer and radiologist reporting of CXR from 
a perspective of the National Health Service using a decision tree to model the pathway from first 
presentation to subsequent treatment. The model simulated a cohort of 1,000 patients in order to 
capture the diagnosis and treatment costs, and the outcomes of screening in terms of cases 
detected at first presentation and quality adjusted life expectancy over the subsequent five years. 
The radiologist reporting arm of the decision tree is shown in Figure 1. The structure of the 
radiographer reporting arm is identical to this. Patients with suspected lung cancer undergo a CXR 
which is reported either by the radiographer or a radiologist. Positive results are confirmed by CT 
scan which provides provisional staging. Treatment of confirmed cases is commenced according to 
disease stage. False negatives are assumed to present at an Emergency department at a later date 
and to receive a confirmatory diagnosis and subsequent treatment.  
A trained radiographer was considered to hold training at masters level on the reporting of CXR and 
to work within the practice framework outlined by the RCR and SCoR.10 Costs and quality adjusted 
life expectancy over five years following diagnosis according to cancer stage were estimated from 
the literature. We evaluated the overall diagnostic costs and the number of cases detected at first 
presentation with radiologist and radiographer reporting. We also estimated the cost per quality 
adjusted life-year (QALY) after including estimates of the cost and quality adjusted life expectancy 
associated with lung cancer diagnosis according to stage at diagnosis. Costs are reported in 2014/15 
GBP and costs and outcomes were discounted at 3.5% following guidelines for cost-effectiveness 
analysis.25 The assumptions underpinning the analysis are shown in Box 1. 
Data sources 
The sensitivity and specificity of CXR reporting by radiographers and radiologists were drawn from a 
diagnostic accuracy study that compared a cohort of consultant radiologists and reporting 
radiographers when interpreting a bank of adult CXR.16  Other parameters for the model were drawn 
from relevant literature sources for non-small cell lung cancer as this type of cancer is present in 
around 90% of cases.26 Parameter values and sources for each branch of the decision tree along with 
relevant unit costs are reported in Table 1. The prevalence of lung cancer amongst presenting 
patients was assumed to be 13%.27 Sensitivity and specificity of CT scan was taken from Aberle et 
al.28 The hourly cost of a radiographer (£53) and a radiologist (£156) were taken from a detailed 
costing study.29 Costs per hour calculated by Lockwood for a reporting radiographer is based on 
salary, on-costs and education (postgraduate certificate for both CT head and CXR) rather than the 
examination/modality reported or output per hour. The £53 per hour radiographer costs is 
transferable to our model.27 We assumed that reporting a CXR would take two minutes,30 generating 
reporting costs of £5.20 for a radiologist and £1.77 for a radiographer in addition to the cost of the 
CXR.31 The diagnosis cost for cases re-presenting at emergency departments was assumed to be the 
cost of an emergency department visit in addition to the cost of a CXR and a CT scan. 
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Disease stage at presentation for initial CXR was taken from data reported by Cancer Research UK 
(Table 2).32 There is a paucity of data on the impact of missed diagnoses. A retrospective analysis of 
CXR in patients with delayed diagnosis reported a median of 155 days from missed abnormal CXR to 
treatment compared with 51 days from first abnormal CXR to treatment in patients correctly 
diagnosed.33 This would suggest that a missed diagnosis on CXR delays diagnosis by 104 days 
Evidence of the impact of treatment delay on cancer stage is also limited. Byrne and co-workers 
report the change in stage between first abnormal imaging and CT-guided biopsy for 66 patients.34 
Over a median of 81 days, 17 patients progressed one stage, 5 progressed two stages and 1 
progressed three stages. We assumed that patients receiving a false negative diagnosis would 
present 104 days later at an emergency department, at which point the proportion of patients 
progressing one or more stages would be as reported in Byrne et al. where progression indicated 
stage beyond IV patients were assumed to remain at stage IV.   
Table 2 also summarises the outcomes of treatment and associated costs over five years applied in 
the model. In the absence of UK data we used SEER data to quantify survival. Survival at 6,18,30,42 
and 54 months according to stage at diagnosis was estimated from published Kaplan-Meier survival 
curves.35 Where stages were subdivided (i.e. stages IA and IB) a weighted average was calculated.  
Mid-year survival was multiplied by quality of life according to stage at diagnosis36 to estimate QALYs 
accrued for that year. Results were discounted at 3.5% and summed over five years. Where 
diagnosis is delayed due to a false negative CXR and patients disease progresses by one stage 
patients were assumed to spend the intervening 104 days in the stage at initial presentation and 
accrued QALYs accordingly (i.e. 0.23 QALYs for patients with stage I disease). This QALY gain was 
added to the QALYs accrued after diagnosis at second presentation 
Treatment costs according to stage of disease were taken from a publication by Cancer Research UK 
(2014) which includes the cost of retreatment after recurrence in the following five years.37 We 
assumed a price year of 2012/13 based on the source of unit costs data for hospital stays and 
inflated costs to 2014/15 values using the Hospital & Community Health Services inflation index.38  
Analysis 
The model reported diagnosis costs, overall costs (diagnosis and treatment), cases detected at first 
presentation and QALYs gained for the cohort of 1,000 patients according to radiographer or 
radiologist reporting. Where one reporting strategy dominated the other (it delivered better 
outcomes at lower cost) we report this. Where one reporting strategy had better outcomes at higher 
cost we calculated an Incremental Cost-Effectiveness Ratio (ICER) which is the incremental cost per 
additional unit of outcome (case detected or QALY). The ICER is the difference in costs divided by the 
difference in outcome for the more effective reporting strategy compared with the less effective 
strategy.  
The impact of parameter uncertainty in our estimates of the prevalence of lung cancer, sensitivity 
and specificity of radiologist and radiographer reporting, lung cancer stage distribution at initial CXR 
and stage progression following misdiagnosis was captured using probabilistic sensitivity analysis. 
We specified these parameters as random variables with Beta distributions (Dirichlet distribution for 
stage progression) derived from the source data. A value was sampled at random from the specified 
distribution for each of these parameters prior to evaluating costs and outcomes. The process was 
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repeated 5,000 times and the mean incremental costs and outcomes determined across the 5,000 
simulations (each simulation followed a cohort of 1,000 patients). 
The key parameter estimates of sensitivity and specificity for radiographer and radiologist reporting 
were drawn from a study which was powered to demonstrate non-inferiority and it is possible that 
differences arose through chance. Hence, in a sensitivity analysis of cost we assumed the same 
sensitivity and specificity for radiographer reporting as observed for radiologist reporting. Our 
analysis also assumed the same reporting times for radiographers and radiologists. In threshold 
analysis we determine the additional reporting time for radiographers at which screening costs are 
equal to those for radiologists. 
 
Results 
Table 3 reports the mean results from 5000 model simulations. Radiographer reporting detects more 
cases at initial presentation with lower diagnosis costs than radiologist reporting in all of the 5000 
model simulations. Costs are modestly lower for radiographer reporting compared with radiologist 
reporting after the inclusion of treatment costs and quality adjusted life expectancy is increased. 
Table 4 provides a breakdown of stage at diagnosis for the 13% (130 patients) of the cohort with 
lung cancer and the QALYs accrued by these patients and their treatment costs over the subsequent 
five years. Increased sensitivity in the radiographer reporting arm results in a very modest shift in 
stage at diagnosis. The increase in patients diagnosed at stage I, for whom prognosis is good, is 
primarily responsible for the modest gain in QALYs accruing to the radiographer reporting arm. The 
shift in stage at diagnosis also generates modestly increased treatment costs in the radiographer 
reporting arm, primarily because treatment costs are lowest for patient in stage IV where life 
expectancy is short. Hence, with respect to overall costs and QALYs radiographer reporting again 
dominates (delivers improved outcomes at lower cost) radiologist reporting. Across the model 
simulations the probability that radiographer reporting dominates radiologist reporting with respect 
to overall costs and QALYs is 98%. 
In sensitivity analysis in which we assumed the same sensitivity and specificity for radiographer and 
radiologist reporting of CXR radiographers remained cheaper than radiologists in all 5,000 
simulations. Threshold analysis indicated that diagnosis costs for radiographer reporting rise to the 
same value as that for radiologist reporting when reporting time for radiographers is increased to 
11.3 minutes. 
 
Discussion 
Main findings and interpretation 
Our analysis indicates that utilising trained radiographers to report CXR is cost-effective. In terms of 
diagnosis costs such a change is likely to save money without compromising detection rates. When 
we include treatment costs and outcomes radiographer reporting remains cost-effective.   
Our findings are underpinned by a study which found improved sensitivity and specificity for trained 
radiographer reporting compared with radiologists but was powered to test non-inferiority, and the 
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differences observed may have been a chance finding. We undertook probabilistic analysis in which 
we propagated the uncertainty in the specificity and sensitivity of both radiographer and radiologist 
reporting through the analysis. The results indicate it is highly likely that radiographer reporting is 
cost-effective despite uncertainty in estimates of sensitivity and specificity. Further sensitivity 
analysis in which we assumed the same sensitivity and specificity for trained radiographers and 
radiologists supports this.  
Our findings support an option to expand the contribution of trained radiographers to report CXR for 
lung cancer. Such a policy would maximise scarce consultant radiologist capacity, concentrating their 
efforts on more complex imaging, multidisciplinary team meetings and interventional procedures. It 
might also help hospitals to meet targets for diagnosis following referral. In addition, radiographers 
may value the role development. For centres with an existing cohort of trained CXR reporting 
radiographers implementation would not require any significant changes in infrastructure or 
personnel. Otherwise, additional education and training, with supervision and mentoring from 
clinical radiologists, will be required to support radiographers in developing reporting skills. 
Strengths and limitations 
In this modelling exercise we draw on the best available evidence on the sensitivity and specificity of 
radiologist and radiographer reporting of CXR to estimate the impact on downstream treatment 
costs and consequences. Our analysis extends beyond traditional consideration of diagnostic 
performance and initial screening costs. We follow good practice guidelines for economic modelling 
and undertook a probabilistic sensitivity analysis to fully capture the impact of sampling variation in 
parameters on cost-effectiveness estimates. In addition to this we have undertaken further 
sensitivity analysis on the assumptions underpinning our analysis. 
There are a number of limitations of this study. Firstly, our analysis is based on a model and all 
models are an abstraction from real life. They do, though, allow us to focus on the most salient parts 
of the care process. Second, our analysis made a number of assumptions, mainly due to a lack of 
available data (box 1). We assumed no difference in sensitivity and specificity according to disease 
stage. In reality, patients at an earlier stage with smaller tumours may be more difficult to diagnose. 
We assumed the same reporting time (2 minutes) for radiographers and radiologists, although 
threshold analysis suggests are results are robust to this assumption. We made some simple 
assumptions on survival, quality of life, and treatment costs following diagnosis. Finally, we have not 
considered the implementation costs of increasing the role and scope of practice of radiographers to 
report CXR. Future research to apply the model developed in the current study to clinical practice 
would address many of limitations identified and allow data to replace assumptions, for example 
implementation costs of implementing radiographer reporting, sensitivity of CXR interpretation, 
patient survival and treatment costs. Current work is underway to investigate.39 
Comparisons with the literature 
An early study of musculo-skeletal radiograph reporting in A&E found a reduction in cases re-
presenting after misdiagnosis along with cost savings following introduction of trained radiographer 
reporting.18 An economic evaluation alongside a RCT of radiographer led immediate reporting of 
musculo-skeletal radiographs also found a reduction in interpretive errors associated with 
immediate reporting.23 The authors disregarded a reduction in QALYs of 0.005 associated with 
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radiographer reporting as a statistical artefact and concluded immediate reporting reduced costs 
without impacting on outcomes. Brown and Desai concluded that Barium enemas were 20% cheaper 
when performed by radiographers compared with radiologists.24 These findings are consistent with 
our analysis. However, our analysis goes further than previous studies in quantifying the cost-
effectiveness of radiographer reporting rather than assuming similar effectiveness and quantifying 
cost savings.  
 
Conclusions 
The use of trained radiographers to report CXR is effective and cost-effective. An increased role for 
radiographers in diagnosis of lung cancer would release precious radiologist resource, could improve 
patient outcomes and may assist hospitals to meet targets on waiting times for diagnosis of lung 
cancer. 
 
Acknowledgements: This project was funded by xxxx  
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Box – assumptions underpinning the analysis 
 
 Time taken to report CXR is 2 minutes for both radiographers and radiologists 
 False negatives present at A&E at a later date at which point disease may have advanced a 
stage (for patients at stage I to III) 
 Sensitivity and specificity of radiographer reporting of CXR and radiologist reporting of both 
CXR and CT-scan is independent of disease stage or other patient characteristics such as age. 
 QOL in the year following diagnosis (according to stage at diagnosis) is maintained in 
subsequent years 
 There is no QOL impact arising from false positive reporting 
 Findings for non-small cell lung cancer are representative for lung cancers in general 
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Table 1. Diagnosis costs and probabilities for chance nodes in the decision tree 
Parameter Value Source 
Chance node probabilities   
Lung cancer prevalence 0.13 Field 201427 
Sensitivity - Radiologist  reporting  CXR 69.7 Woznitza 201616 
Specificity - Radiologist  reporting  CXR 80.9 Woznitza 201616 
Sensitivity - Radiographer reporting CXR 78.1 Woznitza 201616 
Specificity - Radiographer reporting CXR 85.2 Woznitza 201616 
Sensitivity - Radiologist reporting  CT Scan   94.4 Aberle 201328 
Specificity - Radiologist reporting  CT Scan   72.6 Aberle 201328 
Costs   
Cost of CXR  £30 NHS Reference 
Costs 2014/1531 
Total cost of radiologist reporting CXR £35.20 Lockwood 201629  
Total cost of radiographer reporting CXR £31.77 Lockwood 201629  
Cost of A&E treatment £ 141 NHS Reference 
Costs 2014/1531 
CXR – chest radiograph, CT – Computed Tomography, A&E – Accident and Emergency 
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Table 2. Costs and quality adjusted life-years (QALYs) for lung cancer patients following diagnosis 
Cancer stage at diagnosis      
Parameter Stage I Stage II Stage III Stage IV Source 
Stage at first presentation 0.15 0.08 0.22 0.55 CRUK 201332 
Stage at second presentation 
following misdiagnosis 
0.10 0.09 0.18 0.64 CRUK 201332 and 
Byrne 201434 
Quality of life following 
diagnosis 
0.81 0.77 0.76 0.76 Naik 201536 
Total QALYs after discounting 2.95 2.11 1.28 0.52 Survival from 
Groome 200735 
Treatment costs following 
diagnosis 
£ 16,740 £ 19,072 £ 21,408 £ 13,342 CRUK 201437 
CRUK – Cancer Research UK 
 
Table 3 Base case simulation results 
 
Reporting 
Professional 
Diagnosis 
costs (£) 
Diagnosis 
and 
treatment 
costs (£) 
Cases 
detected at 
first 
presentation 
QALYs 
accrued 
ICER (cost 
per QALY, 
£) 
Radiographer 60,149 2,137,983 95.87 148.74 Dominates 
Radiologist 68,642 2,142,299 85.52 147.39  
QALY – quality adjusted life expectancy, ICER – Incremental Cost-Effectiveness Ratio 
Table 4 Distribution of stage at diagnosis and resulting treatment costs and outcomes in 
Radiographer and Radiologist arms 
 
 Stage I Stage II Stage III Stage IV All stages 
Patients diagnosed – 
radiologist reporting 17.2 10.9 26.6 75.3 130.0 
Patients diagnosed – 
radiographer reporting 17.7 10.8 27.1 74.4 130.0 
QALYs gained – 
radiologist reporting 50.7 22.9 34.1 39.7 147.4 
QALYs gained – 
radiographer reporting 52.3 22.7 34.7 39.1 148.7 
Treatment costs (£) – 
radiologist reporting 287,526 207,476 569,712 1,005,099 2,069,813 
Treatment costs (£) – 
radiographer reporting 296,547 205,361 579,576 993,242 2,074,725 
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Figure 1. Radiologist reporting arm of the decision tree. 
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